Research programme: microRNA therapeutics - AstraZeneca/Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - AstraZeneca/Regulus Therapeutics

Alternative Names: anti-microRNA-103/107; anti-microRNA-19; anti-microRNA-33a; anti-microRNA-33b; anti-miR-103/107; anti-miR-19; anti-miR-33a; anti-miR-33b; microRNA-103/107 therapeutics; microRNA-19 therapeutics; microRNA-33 therapeutics

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator AstraZeneca; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Cancer; Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 24 Sep 2014 Preclinical development is ongoing in the US
  • 28 Oct 2013 Preclinical development is ongoing in US
  • 14 Aug 2012 Preclinical trials in Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top